An advisory panel of the Food and Food Administration has unanimously recommended an emergency use authorization for a third modern shot, although only some people would be eligible for reinforcement shot. The recommendation follows the financial details of the second quarter of modern shared in August, which included information about the effectiveness of the COVID-19 vaccine six months after the second dose, as well as the reinforcement of its reinforcement shots to help protect against the SARS-COV-2 variants.
The recommendation comes from advisors with the FDA, racing the way for an emergency use authorization and a second Covid-19 reinforcement shot option in the United States. The regular Modern Vaccination protocol COVID-19 implies managing dose of 100 micrograms in two shots. The reinforcement, if you receive the authorization, will cover a single reinforcement dose of 50 micrograms to help protect those whose immunity can be hesitant.
Only certain people would be eligible for modern reinforcement similar to the dose of Pfizer Booster currently available. Only adults between 18 and 64 would be eligible, assuming that they face a high risk of developing a serious COVID-19 infection. In addition, the same age group would be eligible if their work or other environments put them at risk of developing a serious infection or complications of an infection.
This authorization would expand the number of people in the US. UU. Which are eligible for a third dose beyond only those that have compromised immune systems. That said, the FDA panel also pointed out that the evidence that a third reinforcement is necessary or useful is not entirely solid. However, given the severe nature of the disease and the “imperfect” data currently available, the panel unanimously recommended the reinforcement.
With the recommendation of the advisors, we are likely to see an emergency use authorization granted by the FDA in the near future. In a separate ad, the FDA said that he will soon hold another meeting with the advisors on a possible US for the Oral Covid-19 treatment of Merck and Merck.